QDEL Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of -104.64% compared to QuidelOrtho Corp.'s net margin of -12425.36%. QuidelOrtho Corp.'s return on equity of -41.24% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

QuidelOrtho Corp. has a consensus price target of $37.67, signalling upside risk potential of 30.29%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 349.19%. Given that Perspective Therapeutics, Inc. has higher upside potential than QuidelOrtho Corp., analysts believe Perspective Therapeutics, Inc. is more attractive than QuidelOrtho Corp..

QuidelOrtho Corp. has a beta of 0.584, which suggesting that the stock is 41.596% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

QuidelOrtho Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. QuidelOrtho Corp. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

QuidelOrtho Corp. quarterly revenues are $700.5M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. QuidelOrtho Corp.'s net income of -$733M is lower than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, QuidelOrtho Corp.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QuidelOrtho Corp. is 0.72x versus 190.87x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

iRhythm Technologies, Inc. has a net margin of -104.64% compared to QuidelOrtho Corp.'s net margin of -2.7%. QuidelOrtho Corp.'s return on equity of -41.24% beat iRhythm Technologies, Inc.'s return on equity of -54.18%.

QuidelOrtho Corp. has a consensus price target of $37.67, signalling upside risk potential of 30.29%. On the other hand iRhythm Technologies, Inc. has an analysts' consensus of $218.60 which suggests that it could grow by 24.35%. Given that QuidelOrtho Corp. has higher upside potential than iRhythm Technologies, Inc., analysts believe QuidelOrtho Corp. is more attractive than iRhythm Technologies, Inc..

QuidelOrtho Corp. has a beta of 0.584, which suggesting that the stock is 41.596% less volatile than S&P 500. In comparison iRhythm Technologies, Inc. has a beta of 1.099, suggesting its more volatile than the S&P 500 by 9.93%.

QuidelOrtho Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. QuidelOrtho Corp. pays -- of its earnings as a dividend. iRhythm Technologies, Inc. pays out -- of its earnings as a dividend.

QuidelOrtho Corp. quarterly revenues are $700.5M, which are larger than iRhythm Technologies, Inc. quarterly revenues of $192.9M. QuidelOrtho Corp.'s net income of -$733M is lower than iRhythm Technologies, Inc.'s net income of -$5.2M. Notably, QuidelOrtho Corp.'s price-to-earnings ratio is -- while iRhythm Technologies, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QuidelOrtho Corp. is 0.72x versus 7.95x for iRhythm Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of -104.64% compared to QuidelOrtho Corp.'s net margin of 28.31%. QuidelOrtho Corp.'s return on equity of -41.24% beat Intuitive Surgical, Inc.'s return on equity of 16.38%.

QuidelOrtho Corp. has a consensus price target of $37.67, signalling upside risk potential of 30.29%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $599.60 which suggests that it could grow by 3.89%. Given that QuidelOrtho Corp. has higher upside potential than Intuitive Surgical, Inc., analysts believe QuidelOrtho Corp. is more attractive than Intuitive Surgical, Inc..

QuidelOrtho Corp. has a beta of 0.584, which suggesting that the stock is 41.596% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.682, suggesting its more volatile than the S&P 500 by 68.249%.

QuidelOrtho Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. QuidelOrtho Corp. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.

QuidelOrtho Corp. quarterly revenues are $700.5M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.5B. QuidelOrtho Corp.'s net income of -$733M is lower than Intuitive Surgical, Inc.'s net income of $709.2M. Notably, QuidelOrtho Corp.'s price-to-earnings ratio is -- while Intuitive Surgical, Inc.'s PE ratio is 76.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QuidelOrtho Corp. is 0.72x versus 21.83x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services, Inc. has a net margin of -104.64% compared to QuidelOrtho Corp.'s net margin of 17.41%. QuidelOrtho Corp.'s return on equity of -41.24% beat West Pharmaceutical Services, Inc.'s return on equity of 17.44%.

QuidelOrtho Corp. has a consensus price target of $37.67, signalling upside risk potential of 30.29%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $345.71 which suggests that it could grow by 24.96%. Given that QuidelOrtho Corp. has higher upside potential than West Pharmaceutical Services, Inc., analysts believe QuidelOrtho Corp. is more attractive than West Pharmaceutical Services, Inc..

QuidelOrtho Corp. has a beta of 0.584, which suggesting that the stock is 41.596% less volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.166, suggesting its more volatile than the S&P 500 by 16.617%.

QuidelOrtho Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services, Inc. offers a yield of 0.31% to investors and pays a quarterly dividend of $0.22 per share. QuidelOrtho Corp. pays -- of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.27% of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

QuidelOrtho Corp. quarterly revenues are $700.5M, which are smaller than West Pharmaceutical Services, Inc. quarterly revenues of $804.3M. QuidelOrtho Corp.'s net income of -$733M is lower than West Pharmaceutical Services, Inc.'s net income of $140M. Notably, QuidelOrtho Corp.'s price-to-earnings ratio is -- while West Pharmaceutical Services, Inc.'s PE ratio is 40.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for QuidelOrtho Corp. is 0.72x versus 6.68x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.